Metabolic syndrome in patients with prostate cancer undergoing androgen suppression

Objectives Cardiovascular mortality is the leading cause of death in patients with prostate cancer (PC), metabolic syndrome (MS) being related to it. The main objective of this study was to determine the prevalence of MS in patients with CP undergoing androgen suppression (AS). Materials and methods We performed a retrospective study of cases and controls that included 159 patients. The study group was made up of 53 patients with PC undergoing SA for a period exceeding 12 months. The control group had 53 patients with PC at the time of diagnosis and 53 patients with negative prostate biopsy. All the patients were evaluated for presence of MS according to NCEP-ATPIII criteria. Results Prevalence of MS in patients without PC was 32.1% and in those with non-treated PC 35.8%, P = .324. In patients with PC undergoing AS, prevalence of MS was 50.9%, P